Hemoglobinopathies are among the most common monogenic diseases worldwide. Approximately 1-5% of the global population are carriers for a genetic thalassemia mutation. The thalassemias are characterized by autosomal recessive inherited defects in the production of hemoglobin. They are highly prevalent in the Mediterranean, Middle East, Indian subcontinent, and East and Southeast Asia. Due to recent migrations, however, the thalassemias are now becoming more common in Europe and North America, making this disease a global health concern. Currently available conventional therapies in thalassemia have many challenges and limitations. A better understanding of the pathophysiology of β-thalassemia in addition to key developments in optimizing transfusion programs and iron-chelation therapy has led to an increase in the life span of thalassemia patients and paved the way for new therapeutic strategies. These can be classified into three categories based on their efforts to address different features of the underlying pathophysiology of β-thalassemia: correction of the globin chain imbalance, addressing ineffective erythropoiesis, and improving iron overload. In this review, we provide an overview of the novel therapeutic approaches that are currently in development for β-thalassemia.

Beta thalassemia : New therapeutic options beyond transfusion and iron chelation / I. Motta, R. Bou-Fakhredin, A.T. Taher, M.D. Cappellini. - In: DRUGS. - ISSN 0012-6667. - 80(2020 Jul), pp. 1053-1063. [10.1007/s40265-020-01341-9]

Beta thalassemia : New therapeutic options beyond transfusion and iron chelation

I. Motta
Primo
;
R. Bou-Fakhredin;M.D. Cappellini
Ultimo
2020

Abstract

Hemoglobinopathies are among the most common monogenic diseases worldwide. Approximately 1-5% of the global population are carriers for a genetic thalassemia mutation. The thalassemias are characterized by autosomal recessive inherited defects in the production of hemoglobin. They are highly prevalent in the Mediterranean, Middle East, Indian subcontinent, and East and Southeast Asia. Due to recent migrations, however, the thalassemias are now becoming more common in Europe and North America, making this disease a global health concern. Currently available conventional therapies in thalassemia have many challenges and limitations. A better understanding of the pathophysiology of β-thalassemia in addition to key developments in optimizing transfusion programs and iron-chelation therapy has led to an increase in the life span of thalassemia patients and paved the way for new therapeutic strategies. These can be classified into three categories based on their efforts to address different features of the underlying pathophysiology of β-thalassemia: correction of the globin chain imbalance, addressing ineffective erythropoiesis, and improving iron overload. In this review, we provide an overview of the novel therapeutic approaches that are currently in development for β-thalassemia.
Settore MED/09 - Medicina Interna
Settore MED/15 - Malattie del Sangue
lug-2020
15-giu-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
Motta2020_Article_BetaThalassemiaNewTherapeuticO.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 815.6 kB
Formato Adobe PDF
815.6 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Motta2020_Article_BetaThalassemiaNewTherapeuticO.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 754.09 kB
Formato Adobe PDF
754.09 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/742723
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 47
  • ???jsp.display-item.citation.isi??? 43
social impact